Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.Financial_Report.xls
10-Q - ERGO 10-Q 09/30/12 - Entia Biosciences, Inc.ergo10q_093012apg.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R36.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R42.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R43.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R40.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R34.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R31.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R29.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R37.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R35.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R32.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R33.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R39.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R28.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R23.htm
EX-32.1 - EXHIBIT 32.1 - Entia Biosciences, Inc.ex32_1apg.htm
EX-31.1 - EXHIBIT 31.1 - Entia Biosciences, Inc.ex31_1apg.htm
EX-32.2 - EXHIBIT 32.2 - Entia Biosciences, Inc.ex32_2apg.htm
EX-31.2 - EXHIBIT 31.2 - Entia Biosciences, Inc.ex31_2apg.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R26.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R41.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R38.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R30.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R27.htm
v2.4.0.6
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)
Preferred Stock
Common Stock
Additional Paid In Capital
Deferred Compensation
Stock Subscriptions
Accumulated Deficit
Total
Beginning Balance, Amount at Dec. 31, 2010   $ 5,836 $ 2,011,989 $ (9,704)   $ (2,313,274) $ (305,153)
Beginning Balance, Shares at Dec. 31, 2010 0 5,836,247          
Conversion of note payable into preferred stock, Shares 21,500            
Conversion of note payable into preferred stock, Amount 22   107,480       107,500
Issuance of preferred stock for cash, Shares 22,000            
Issuance of preferred stock for cash, Amount 22   109,978       110,000
Issuance of warrants in connection with convertible notes payable     45,937       45,937
Beneficial conversion feature in connection with convertible notes payable     173,030       173,030
Issuance of common stock for license agreement, Shares   100,000          
Issuance of common stock for license agreement, Amount   100 99,900       100,000
Issuance of common stock for conversion of accounts payable/accrued comp, Shares   897,104          
Issuance of common stock for conversion of accounts payable/accrued comp, Amount   935 368,875       369,810
Issuance of common stock for services, Shares   276,395          
Issuance of common stock for services, Amount   238 243,758       243,996
Issuance of common stock and warrants for cash, Shares   61,429          
Issuance of common stock and warrants for cash, Amount   62 42,938       43,000
Stock compensation, Amount     347,969       347,969
Issuance of warrants for services     721,213 (721,213)      
Amortization of deferred compensation       225,079     225,079
Net loss           (1,729,103) (1,729,103)
Ending Balance, amount at Dec. 31, 2011 44 7,171 4,272,792 (497,383)   (4,042,376) (259,752)
Ending Balance, shares at Dec. 31, 2011 43,500 7,171,175          
Issuance of preferred stock for cash, Shares 36,400            
Issuance of preferred stock for cash, Amount 36   181,963       181,999
Issuance of preferred stock for cancellation of debt, Shares 2,000            
Issuance of preferred stock for cancellation of debt, Amount 2   9,998       10,000
Issuance of preferred stock for services, Shares 7,000            
Issuance of preferred stock for services, Amount 7   34,993       35,000
Deemed dividend related to beneficial conversion feature of convertible preferred stock, Shares     21,400     (21,400)  
Issuance of warrants in connection with convertible notes payable     27,704       27,704
Issuance of common stock for license agreement, Shares   50,000          
Issuance of common stock for license agreement, Amount   50 25,451       25,501
Issuance of common stock and warrants for cash, Shares   75,000          
Issuance of common stock and warrants for cash, Amount   75 29,925       30,000
Stock compensation, Shares   666          
Stock compensation, Amount   1 170,740       170,740
Issuance of warrants for services     21,139 (21,139)      
Issuance of warrants for extension on debt     48,533       48,533
Amortization of deferred compensation       141,026     141,026
Net loss           (974,602) (974,602)
Ending Balance, amount at Sep. 30, 2012 $ 89 $ 7,444 $ 4,903,491 $ (377,496) $ (59,000) $ (5,038,378) $ (563,850)
Ending Balance, shares at Sep. 30, 2012 88,900 7,444,341